Patients with prostate cancer were found to have increased expression of the lncRNA PCA3 in sEVs obtained from their urine; therefore, PCA3 in urine-derived sEVs can be used as a marker for the early diagnosis of PCa [95]. The gene discussed is PCA3; the disease is posterior cortical atrophy.